BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Core Insights - BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [1][4] - The company will present two clinical data posters at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting scheduled for October 17-21 in Berlin, Germany [1] Presentation Details - The first poster presentation is titled "Phase III Pivotal Trial of Bria-IMT + CPI vs Physician's Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)" [3] - The second poster presentation is titled "Feasibility and Biomarker Validation of an International Randomized Phase 3 Trial of Bria-IMT Cell Therapy in Late Stage MBC (BRIA-ABC)" [3] - Abstracts for these presentations will be published online on the ESMO website on October 13, 2025 [3] Company Information - BriaCell is dedicated to developing innovative immunotherapies for cancer treatment [4] - More information about the company can be found on their official website [4]